EXACT Sciences Corporation (EXAS) - Net Assets
Based on the latest financial reports, EXACT Sciences Corporation (EXAS) has net assets worth $2.40 Billion USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($5.86 Billion) and total liabilities ($3.46 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are EXACT Sciences Corporation's assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $2.40 Billion |
| % of Total Assets | 40.97% |
| Annual Growth Rate | 22.84% |
| 5-Year Change | -29.12% |
| 10-Year Change | 616.1% |
| Growth Volatility | 257.86 |
EXACT Sciences Corporation - Net Assets Trend (1998–2025)
This chart illustrates how EXACT Sciences Corporation's net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of EXACT Sciences Corporation for the complete picture of this company's asset base.
Annual Net Assets for EXACT Sciences Corporation (1998–2025)
The table below shows the annual net assets of EXACT Sciences Corporation from 1998 to 2025. For live valuation and market cap data, see EXACT Sciences Corporation (EXAS) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $2.40 Billion | -0.05% |
| 2024-12-31 | $2.40 Billion | -23.62% |
| 2023-12-31 | $3.15 Billion | +3.36% |
| 2022-12-31 | $3.04 Billion | -10.17% |
| 2021-12-31 | $3.39 Billion | +51.53% |
| 2020-12-31 | $2.24 Billion | -2.29% |
| 2019-12-31 | $2.29 Billion | +236.01% |
| 2018-12-31 | $680.94 Million | +30.85% |
| 2017-12-31 | $520.42 Million | +55.21% |
| 2016-12-31 | $335.30 Million | +2.58% |
| 2015-12-31 | $326.86 Million | +13.11% |
| 2014-12-31 | $288.98 Million | +113.56% |
| 2013-12-31 | $135.32 Million | +37.24% |
| 2012-12-31 | $98.59 Million | +18.08% |
| 2011-12-31 | $83.50 Million | +4.69% |
| 2010-12-31 | $79.75 Million | +1208.73% |
| 2009-12-31 | $6.09 Million | +350.47% |
| 2008-12-31 | $-2.43 Million | -138.69% |
| 2007-12-31 | $6.29 Million | -57.96% |
| 2006-12-31 | $14.96 Million | -39.25% |
| 2005-12-31 | $24.62 Million | -35.18% |
| 2004-12-31 | $37.98 Million | +210.62% |
| 2003-12-31 | $12.23 Million | -68.11% |
| 2002-12-31 | $38.35 Million | -34.97% |
| 2001-12-31 | $58.97 Million | +112.88% |
| 2000-12-31 | $27.70 Million | +528.11% |
| 1999-12-31 | $4.41 Million | -52.57% |
| 1998-12-31 | $9.30 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to EXACT Sciences Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 470598100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.91 Million | 0.08% |
| Other Comprehensive Income | $2.36 Million | 0.10% |
| Other Components | $7.10 Billion | 295.82% |
| Total Equity | $2.40 Billion | 100.00% |
EXACT Sciences Corporation Competitors by Market Cap
The table below lists competitors of EXACT Sciences Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Albemarle Corp
NYSE:ALB
|
$19.80 Billion |
|
Yuanjie Semiconductor Technology Co. Ltd. A
SHG:688498
|
$19.81 Billion |
|
New China Life Insurance Co Ltd
SHG:601336
|
$19.84 Billion |
|
Allegheny Technologies Incorporated
NYSE:ATI
|
$19.84 Billion |
|
China Spacesat Co Ltd
SHG:600118
|
$19.76 Billion |
|
IHH Healthcare Bhd
KLSE:5225
|
$19.72 Billion |
|
Telus Corp
TO:T
|
$19.72 Billion |
|
Jardine Matheson Holdings Limited
F:H4W
|
$19.71 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in EXACT Sciences Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,402,249,000 to 2,401,052,000, a change of -1,197,000 (-0.0%).
- Net loss of 207,949,000 reduced equity.
- Share repurchases of 26,544,000 reduced equity.
- Other comprehensive income increased equity by 3,302,000.
- Other factors increased equity by 229,994,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-207.95 Million | -8.66% |
| Share Repurchases | $26.54 Million | -1.11% |
| Other Comprehensive Income | $3.30 Million | +0.14% |
| Other Changes | $229.99 Million | +9.58% |
| Total Change | $- | -0.05% |
Book Value vs Market Value Analysis
This analysis compares EXACT Sciences Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 143.02x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 286.10x to 143.02x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1998-12-31 | $6.36 | $1819.87 | x |
| 1999-12-31 | $3.02 | $1819.87 | x |
| 2000-12-31 | $18.95 | $1819.87 | x |
| 2001-12-31 | $3.58 | $1819.87 | x |
| 2002-12-31 | $2.08 | $1819.87 | x |
| 2003-12-31 | $0.65 | $1819.87 | x |
| 2004-12-31 | $1.50 | $1819.87 | x |
| 2005-12-31 | $0.94 | $1819.87 | x |
| 2006-12-31 | $0.56 | $1819.87 | x |
| 2007-12-31 | $0.23 | $1819.87 | x |
| 2008-12-31 | $-0.09 | $1819.87 | x |
| 2009-12-31 | $0.19 | $1819.87 | x |
| 2010-12-31 | $1.97 | $1819.87 | x |
| 2011-12-31 | $1.59 | $1819.87 | x |
| 2012-12-31 | $1.66 | $1819.87 | x |
| 2013-12-31 | $2.00 | $1819.87 | x |
| 2014-12-31 | $3.60 | $1819.87 | x |
| 2015-12-31 | $3.55 | $1819.87 | x |
| 2016-12-31 | $3.28 | $1819.87 | x |
| 2017-12-31 | $4.50 | $1819.87 | x |
| 2018-12-31 | $5.57 | $1819.87 | x |
| 2019-12-31 | $17.43 | $1819.87 | x |
| 2020-12-31 | $14.79 | $1819.87 | x |
| 2021-12-31 | $19.77 | $1819.87 | x |
| 2022-12-31 | $17.26 | $1819.87 | x |
| 2023-12-31 | $17.46 | $1819.87 | x |
| 2024-12-31 | $13.04 | $1819.87 | x |
| 2025-12-31 | $12.72 | $1819.87 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently EXACT Sciences Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -8.66%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -6.40%
- • Asset Turnover: 0.55x
- • Equity Multiplier: 2.44x
- Recent ROE (-8.66%) is above the historical average (-54.85%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1998 | -38.48% | 0.00% | 0.00x | 1.04x | $-4.51 Million |
| 1999 | -112.56% | 0.00% | 0.00x | 1.08x | $-5.40 Million |
| 2000 | -42.90% | -1188311900.00% | 0.00x | 1.05x | $-14.65 Million |
| 2001 | -39.83% | -46167.53% | 0.00x | 1.07x | $-29.38 Million |
| 2002 | -77.92% | -3331.44% | 0.02x | 1.31x | $-33.72 Million |
| 2003 | -231.76% | -976.90% | 0.08x | 2.84x | $-29.56 Million |
| 2004 | -48.77% | -375.34% | 0.09x | 1.48x | $-22.32 Million |
| 2005 | -58.97% | -341.65% | 0.11x | 1.54x | $-16.98 Million |
| 2006 | -86.34% | -271.89% | 0.20x | 1.60x | $-14.41 Million |
| 2007 | -190.19% | -407.46% | 0.20x | 2.32x | $-12.59 Million |
| 2008 | 0.00% | 0.00% | -0.15x | 0.00x | $-9.50 Million |
| 2009 | -149.15% | -191.03% | 0.18x | 4.23x | $-9.70 Million |
| 2010 | -14.49% | -216.24% | 0.06x | 1.21x | $-19.53 Million |
| 2011 | -34.34% | -688.81% | 0.04x | 1.16x | $-37.02 Million |
| 2012 | -53.17% | -1264.99% | 0.04x | 1.14x | $-62.28 Million |
| 2013 | -34.37% | -1122.44% | 0.03x | 1.08x | $-60.05 Million |
| 2014 | -34.62% | -5564.40% | 0.01x | 1.08x | $-128.95 Million |
| 2015 | -48.28% | -400.14% | 0.11x | 1.11x | $-190.49 Million |
| 2016 | -49.87% | -168.26% | 0.26x | 1.12x | $-200.74 Million |
| 2017 | -21.98% | -43.01% | 0.44x | 1.15x | $-166.44 Million |
| 2018 | -25.72% | -38.54% | 0.30x | 2.24x | $-243.24 Million |
| 2019 | -9.31% | -24.32% | 0.25x | 1.53x | $-441.90 Million |
| 2020 | -36.84% | -55.22% | 0.30x | 2.20x | $-1.05 Billion |
| 2021 | -17.58% | -33.71% | 0.26x | 1.97x | $-934.39 Million |
| 2022 | -20.49% | -29.91% | 0.33x | 2.05x | $-927.82 Million |
| 2023 | -6.49% | -8.17% | 0.39x | 2.06x | $-518.68 Million |
| 2024 | -42.83% | -37.29% | 0.47x | 2.47x | $-1.27 Billion |
| 2025 | -8.66% | -6.40% | 0.55x | 2.44x | $-448.05 Million |
Industry Comparison
This section compares EXACT Sciences Corporation's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $1,070,543,837
- Average return on equity (ROE) among peers: -63.38%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| EXACT Sciences Corporation (EXAS) | $2.40 Billion | -38.48% | 1.44x | $19.80 Billion |
| Agilent Technologies Inc (A) | $4.75 Billion | 22.56% | 0.99x | $32.73 Billion |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $8.45 Million |
| Applied DNA Sciences Inc (APDN) | $-4.71 Million | 0.00% | 0.00x | $3.99 Million |
| Biodesix Inc (BDSX) | $20.61 Million | -317.61% | 3.51x | $79.44 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-4.04 Million | 0.00% | 0.00x | $9.13 Million |
| Biocept Inc. (BIOCQ) | $23.69 Million | -75.16% | 1.00x | $262.00 |
| BillionToOne, Inc. Class A Common Stock (BLLN) | $167.75 Million | -24.78% | 0.80x | $3.79 Billion |
| Burning Rock Biotech Ltd (BNR) | $2.42 Billion | -16.82% | 0.10x | $151.41 Million |
| CareDx Inc (CDNA) | $-150.67 Million | 0.00% | 0.00x | $1.00 Billion |
| Check Cap Ltd (CHEK) | $6.23 Million | -221.94% | 0.51x | $9.42 Million |
About EXACT Sciences Corporation
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer; Cologuard Plus Tests; Cancerguard Test; and Genetic Testing. The company also provides Oncotype DX Breast Recurrence S… Read more